A new kind of CRISPR that destroys cells rather than gene editing them has shown potential for killing sick cells while leaving healthy cells untouched. The technology has largely been tested in cells ...

Before you decide whether CRISPR Therapeutics stock looks attractive at around US$52.38, it helps to ask a simple question: ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...

CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of ...

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first ...

CRISPR Therapeutics CRSP reported a first-quarter 2026 loss of $1.28 per share, wider than the Zacks Consensus Estimate of a loss of $1.14. The company had incurred a loss of $1.58 in the year-ago ...

CRISPR Therapeutics proved the strength of its technology a couple of years ago when it won approval for its first product.

Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

CRISPR gene therapy increases haemoglobin and fetal haemoglobin in sickle cell disease, reducing vaso occlusive events in ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

We'll know more about the company's medium-term prospects by the end of the year.

When activated by its target, the newly characterized molecule rips the genome apart, a lethal move that researchers can ...